文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌新辅助治疗的系统综述与荟萃分析更新

Neoadjuvant Therapy in Patients with Upper Tract Urothelial Cancer: An Updated Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2026-10-26

该研究系统更新了新辅助化疗(NAC)在非转移性上尿路尿路上皮癌(UTUC)中的病理与肿瘤学结局证据,并概述了新辅助免疫治疗(NAI)的现状。纳入41项研究,其中30项(5项前瞻性研究或RCT及25项回顾性研究,n=2384)进入荟萃分析,显示NAC与更优的OS和CSS相关,但证据强度受缺乏前瞻性随机研究限制。

要点

  • NAC组汇总pCR率11%、pPR率44%、病理降期率20%。
  • 与单纯RNU相比,NAC的OS的HR为0.56(95%CI 0.39-0.80)。
  • NAI证据样本量有限,主要来自早期研究。

核心结论

  • 与单纯根治性肾输尿管切除术相比,新辅助化疗与更有利的肿瘤学结局相关。
  • 缺乏前瞻性随机研究限制了证据强度,需进一步高质量试验确认。

研究设计与样本

  • 系统综述纳入41项NAC和NAI研究(8项前瞻性研究或RCT及33项回顾性研究)。
  • 其中30项(5项前瞻性研究或RCT及25项回顾性研究,n=2384例患者)纳入荟萃分析。

主要发现

  • 汇总pCR率为11%(95%CI 10-12),pPR率为44%(95%CI 38-50),病理降期率为20%(95%CI 10-37)。
  • 与RNU相比,NAC的OS的HR为0.56(95%CI 0.39-0.80),CSS的HR为0.47(95%CI 0.26-0.85),DFS的HR为0.55(95%CI 0.24-1.26)。
  • NAI证据在样本量方面仍然有限,主要来自早期阶段研究。

临床怎么用

  • 在非转移性UTUC患者中,新辅助化疗可考虑用于改善肿瘤学结局,但需个体化评估。
  • 新辅助免疫治疗目前证据不足,不宜作为常规推荐。

局限性

  • 缺乏前瞻性随机研究,证据强度有限。
  • 新辅助免疫治疗证据样本量有限,主要来自早期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The role of neoadjuvant chemotherapy (NAC) in patients with upper tract urothelial carcinoma (UTUC) remains controversial, mainly because of the lack of high-level evidence. OBJECTIVE: We aim to update the evidence on NAC regarding pathological and oncological outcomes in patients with nonmetastatic UTUC. Moreover, we also aimed to give an overview of neoadjuvant immunotherapy (NAI) in the current clinical scenario. EVIDENCE ACQUISITION: A systematic review of 41 studies on NAC and NAI (eight prospective studies [PS] or randomized clinical trials [RCTs] and 33 retrospective studies [RS]) was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Outcomes of interest included pathological complete response (pCR), pathological partial response (pPR), pathological downstaging, overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Pooled analyses were performed using effect sizes for pathological outcomes and hazard ratios (HRs) for survival outcomes. Finally, 5-yr proportions were summarized when a 5-yr time threshold was available. EVIDENCE SYNTHESIS: Of the 41 articles, 30 (five PS or RCTs and 25 RS) were eligible for meta-analysis (n = 2384 patients). The pooled pCR, pPR, and pathological downstaging rates were, respectively, 11% (95% confidence interval [CI]: 10-12), 44% (95% CI: 38-50), and 20% (95% CI: 10-37). Compared with radical nephroureterectomy (RNU), NAC was associated with pooled HRs of 0.56 (95% CI: 0.39-0.80) for OS, 0.47 (95% CI: 0.26-0.85) for CSS, and 0.55 (95% CI: 0.24-1.26) for DFS. Evidence on NAI remains limited in terms of sample size and is primarily derived from early-phase studies. CONCLUSIONS: NAC was associated with favorable oncological outcomes compared with RNU alone. Nevertheless, the absence of prospective randomized studies limits the strength of the evidence, and further high-quality trials are warranted to confirm these findings.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Di Bello F, Gallioli A, D'Andrea D, et al. Neoadjuvant Therapy in Patients with Upper Tract Urothelial Cancer: An Updated Systematic Review and Meta-analysis. Eur Urol Oncol. 2026. PMID: 42934012. doi:10.1016/j.euo.2026.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。